Basics of HRT Management

Education-first hormone care for real women, not headlines

Hormone replacement therapy (HRT) sits at the crossroads of biology, history, and misunderstanding. If this is your first time hearing this explained clearly and without fear, you’re in good company. Many women—and many clinicians—were never given a practical education in menopause medicine. What most people inherited instead were headlines, half-truths, and a general sense that hormones are “dangerous.”

At My V Clinic, we see the downstream effects of that confusion every day. Women arrive exhausted, frustrated, and often told that what they’re feeling is simply stress, aging, or something they should push through. Hot flashes disrupt sleep. Brain fog undermines confidence at work. Vaginal and urinary symptoms quietly erode comfort and intimacy. None of this is rare, and none of it is trivial.

The truth is simpler and more grounded than the noise suggests. Hormones are tools. Like any tool, they must be used correctly, at the right dose, for the right person, and with appropriate follow-up. When that happens, outcomes are predictable and safety is well understood. When fear drives decisions instead of physiology, women pay the price.

This guide explains the basics of HRT management as it is practiced responsibly today. We’ll walk through what hormones actually do, why older studies were misapplied, how modern therapy is structured, and what safe, effective prescribing looks like in real clinical settings. This is not about trends or shortcuts. It’s about restoring clarity to an area of care that affects half the population.

Why HRT still causes confusion

Much of today’s fear traces back to early interpretations of the Women’s Health Initiative (WHI) studies. Those trials examined specific oral synthetic hormone combinations, administered to an older population, and their conclusions were widely generalized to all hormone therapy. Context was lost.

What followed was not a replacement education on how to prescribe hormones safely, but rather a void. A generation of clinicians learned what not to do without learning what to do instead. As a result, fewer women today receive hormone therapy than before the WHI—despite decades of additional data and improved delivery methods.

Modern hormone care accounts for:

• Differences in formulation (synthetic vs bioidentical)
• Differences in delivery (oral vs transdermal vs local)
• Differences in timing (early vs late initiation)
• Differences in goals (symptom relief vs tissue protection)

When those variables are ignored, hormone therapy appears risky. When they are respected, care becomes precise.

The first distinction that matters: systemic vs local hormones

One of the most important foundations in hormone care is understanding where the hormone acts.

Systemic hormone therapy

Systemic hormones circulate through the bloodstream and affect the whole body. They are used to address:

• Hot flashes and night sweats
• Sleep disruption
• Mood and cognitive changes
• Bone density protection
• Metabolic and cardiovascular support when started appropriately

Common systemic estrogen options include:

• Transdermal estrogen patches
• Estrogen gels or sprays
• Estrogen rings designed for systemic absorption

Systemic therapy is about global symptom relief and long-term protection.

Local (vaginal) hormone therapy

Local therapy targets vaginal, vulvar, urethral, and bladder tissue with minimal systemic absorption. These therapies address:

• Vaginal dryness or burning
• Pain with sex
• Recurrent urinary tract infections
• Urinary urgency, frequency, or irritation
• Genitourinary Syndrome of Menopause (GSM)

Local therapy is not interchangeable with systemic therapy. It treats a different problem, in a different way, and carries a different safety profile.

What “bioidentical” actually means

“Bioidentical” refers to hormones that are chemically identical to those produced by the human body. This is not a marketing label—it’s a pharmacologic distinction.

A practical way to understand it:

• If a hormone can be measured meaningfully in the bloodstream and responds predictably to dose changes, it is bioidentical
• Many older synthetic hormones do not behave this way

Why this matters:

• Bioidentical hormones interact with receptors more predictably
• Transdermal delivery avoids unnecessary liver metabolism
• Data from older synthetic oral hormone studies cannot be automatically applied to modern therapy

Grouping all “hormones” together creates confusion that doesn’t reflect how medicine actually works.

What the WHI really tells us

Much of the modern reframing of hormone therapy has been driven by clinicians who work daily at the intersection of urology, sexual medicine, and menopause care. One of the most cited voices in this space is Dr. Rachel Rubin, a urologist and sexual medicine specialist who has spent years educating both clinicians and regulators on how WHI findings were misapplied to contemporary hormone care.

In long-form clinical discussions and FDA advocacy work, Dr. Rubin has emphasized that WHI outcomes reflected specific oral synthetic hormone combinations, not the transdermal, bioidentical regimens most commonly used today. Her work highlights why delivery method, dose, and patient age at initiation fundamentally change risk profiles.

The WHI did not prove that all hormones are unsafe. It demonstrated outcomes associated with one specific oral synthetic regimen, given to women whose average age was well past menopause. Modern practice looks very different:

• Transdermal estrogen is commonly used to reduce clot-related risk
• Micronized progesterone replaces older synthetic progestins
• Dosing is individualized rather than standardized
• Therapy is started earlier, when appropriate

Context matters. Timing matters. Delivery matters.

The WHI did not prove that all hormones are unsafe. It demonstrated outcomes associated with one specific oral synthetic regimen, given to women whose average age was well past menopause.

Modern practice looks very different:

• Transdermal estrogen is commonly used to reduce clot-related risk
• Micronized progesterone replaces older synthetic progestins
• Dosing is individualized rather than standardized
• Therapy is started earlier, when appropriate

Context matters. Timing matters. Delivery matters.

Starting systemic estrogen: a practical approach

Current prescribing standards are increasingly aligned with guidance from professional societies such as the North American Menopause Society (NAMS), which emphasizes individualized dosing, appropriate timing, and route of administration. According to NAMS, hormone therapy remains the most effective treatment for vasomotor symptoms and can be safely used in appropriately selected patients when started within the recommended window.

Estrogen is the backbone of most HRT plans. It addresses vasomotor symptoms and provides protective benefits that extend beyond symptom control.

A common starting strategy

A frequently used approach is a moderate-dose transdermal estradiol patch, applied twice weekly. This allows:

• Stable blood levels
• Easy dose adjustment
• Avoidance of first-pass liver metabolism

Starting too low often leads to persistent symptoms and the mistaken belief that hormones are ineffective. Dosing should be sufficient to produce meaningful relief, then adjusted based on response and tolerance.

Estrogen is the backbone of most HRT plans. It addresses vasomotor symptoms and provides protective benefits that extend beyond symptom control.

A common starting strategy

A frequently used approach is a moderate-dose transdermal estradiol patch, applied twice weekly. This allows:

• Stable blood levels
• Easy dose adjustment
• Avoidance of first-pass liver metabolism

Starting too low often leads to persistent symptoms and the mistaken belief that hormones are ineffective. Dosing should be sufficient to produce meaningful relief, then adjusted based on response and tolerance.

Why vaginal therapy is often still required

Systemic estrogen does not reliably reach vaginal and urinary tissue in therapeutic concentrations. This is why women may report improvement in hot flashes but continue to experience pain with sex or recurrent UTIs.

Clinical guidelines emphasize:

• Screening all midlife women for GSM
• Adding vaginal therapy when symptoms are present

This is not over-treatment. It is targeted care.

Progesterone: protection and added benefits

Women with a uterus require progesterone to protect the uterine lining when using systemic estrogen.

Common options include:

• Micronized oral progesterone
• Progestin-releasing IUDs

Micronized progesterone is often favored because it is bioidentical and commonly supports sleep and mood through calming neurotransmitter pathways. Some women are sensitive and require alternative strategies.

For women without a uterus, progesterone may be used selectively for sleep or anxiety support but is not mandatory.

Testosterone: an essential but overlooked hormone

Testosterone plays a meaningful role in women’s health. Levels decline with age, and symptoms may include:

• Low libido
• Loss of motivation or vitality
• Reduced sexual response
• Certain urinary or pelvic floor changes

When added thoughtfully, many women report a delayed but profound improvement, often describing a return to feeling like themselves.

Typical prescribing involves:

• Transdermal formulations
• Female-appropriate dosing using male products
• Gradual adjustment

This is physiologic replacement, not excess.

Lab testing: support, not supremacy

At My V Clinic, labs are used as supporting data. They help identify absorption issues, establish baselines, and guide adjustments when symptoms and expectations don’t align.

Symptoms remain central. Numbers inform the story; they do not replace it.

DHEA and local androgen support

Local androgen support has gained increasing recognition in menopause guidelines. Vaginal tissue contains both estrogen and androgen receptors, which is why estrogen alone does not always resolve GSM symptoms.

The U.S. Food and Drug Administration (FDA) has approved vaginal DHEA (prasterone) specifically for moderate to severe dyspareunia due to menopause. Unlike oral supplements, this therapy acts locally, supporting tissue integrity, lubrication, and urinary health with minimal systemic exposure.

Oral DHEA is not routinely used.

Vaginal DHEA may be considered when:

• Vaginal estrogen alone is insufficient
• Pain with sex persists
• Recurrent urinary symptoms continue despite treatment

This approach is supported by evolving clinical guidance and reflects a more complete understanding of pelvic tissue physiology.

Oral DHEA is not routinely used.

Vaginal DHEA plays a distinct role in GSM by supporting tissue that contains androgen receptors. It may improve comfort, arousal, lubrication, and urinary health—particularly when estrogen alone is insufficient.

Ongoing research and emerging evidence

Menopause medicine continues to evolve. Research into estrogen receptors in the brain, vascular timing hypotheses, and androgen roles in pelvic health is expanding. Evidence increasingly supports early, individualized therapy rather than blanket avoidance.

As data grows, guidelines adapt—but the core principles of physiology-driven care remain consistent.

The most common mistake in hormone care

Fear-based under-treatment leads to unnecessary suffering. Effective HRT management requires informed confidence, not hesitation.Where My V Clinic fits in

My V Clinic provides education-first, individualized hormone care for women in Thornton and the greater Denver area. We prioritize physiology, evidence, and follow-up—never trends or shortcuts. 81 W 84th Ave, Thornton, CO 80260

Hormones are tools. Used correctly, they restore comfort, function, and quality of life.